BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 22, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» METTL3 inhibitor shows efficacy and synergy with venetoclax in preclinical models of AML
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
METTL3 inhibitor shows efficacy and synergy with venetoclax in preclinical models of AML
Dec. 29, 2023
No Comments
Researchers from Epics Therapeutics SA presented preclinical data for EP-102, a novel small-molecule inhibitor of
N
6-adenosine-methyltransferase catalytic subunit (METTL3), being developed for the treatment of cancer.
BioWorld Science
Conferences
American Society of Hematology
Cancer
